Trial Profile
Phase Ib Dose Escalating Study to Evaluate the Safety, Tolerability and Pharmacodynamic Response of Foxy-5 in Patients With Metastatic Breast-, Colon- or Prostate Cancer
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Foxy 5 (Primary)
- Indications Advanced breast cancer; Colon cancer; Prostate cancer
- Focus Adverse reactions
- Sponsors WntResearch
- 28 Dec 2018 Status changed from recruiting to completed.
- 21 Mar 2017 Results published in WntResearch media release.
- 04 Jan 2017 Planned number of patients changed from 18 to 15.